The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in emerging markets.

A single dose of a chromium-enriched glucomannan-fructo-oligosaccharide fiber complex significantly reduced postprandial ...

We have five products that will launch in the next 12-18 months. We recently launched Yesintek in the immunology space -- a ...

In general, insulins used in children are rapid-acting insulin analogs, short-acting insulin, intermediate-acting insulin (NPH and Lente), and long-acting insulin analogs. These insulins are used ...

Demographic trends are strengthened by a market shift from human insulin toward modern insulin analogs (Novo's Levemir and NovoLog), next-generation insulin analogs (Tresiba, Fiasp), and a novel ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

In a week marked by volatility, global markets faced renewed tariff threats and rising Treasury yields, causing major indices to decline. Amid these fluctuations, the resilience of growth companies ...

Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

Bengaluru: Biocon Limited, a global biopharmaceutical company, has announced that the company has received approval in India ...

The Affordable Insulin Now Act, as it is known ... combining the effects of GLP-1 with other treatments, such as with an analogue of the hormone amylin, to improve outcomes in type 2 diabetes.